Neeta Pandit-Taskar, Ellen Basu, Ali Pirasteh, Gerald Behr, Audrey Mauguen, Jazmin Schwartz, Serge Lyashchenko, Scott Vietri, Eva Burnazi, Anita P. Price, Shakeel Modak
{"title":"18f -偏氟苯胍PET成像在神经母细胞瘤中的病变分析","authors":"Neeta Pandit-Taskar, Ellen Basu, Ali Pirasteh, Gerald Behr, Audrey Mauguen, Jazmin Schwartz, Serge Lyashchenko, Scott Vietri, Eva Burnazi, Anita P. Price, Shakeel Modak","doi":"10.2967/jnumed.125.269833","DOIUrl":null,"url":null,"abstract":"<p>A PET analog of metaiodobenzylguanidine (MIBG)—<sup>18</sup>F-metafluorobenzylguanidine (<sup>18</sup>F-MFBG)—allows for rapid same-day imaging. We previously reported on the safety and feasibility of <sup>18</sup>F-MFBG PET imaging in patients with neuroendocrine tumors. We now report a comprehensive analysis of lesion detection with <sup>18</sup>F-MFBG imaging in patients with neuroblastoma compared with <sup>123</sup>I-MIBG imaging. <strong>Methods:</strong> We analyzed concurrent <sup>18</sup>F-MFBG and <sup>123</sup>I-MIBG scans in 37 patients (40 paired scans). Patients with relapsed or refractory neuroblastoma were included. Patients received 74.11–465.83 MBq (2.0–12.6 mCi) of <sup>18</sup>F-MFBG intravenously, followed by imaging 60 min after injection. All patients had an <sup>123</sup>I-MIBG scan within 4 wk of <sup>18</sup>F-MFBG imaging without any intervening therapy. <sup>123</sup>I-MIBG scans included whole-body planar and SPECT/CT of the chest, abdomen, and pelvis. All detected lesions were noted for each modality. <sup>123</sup>I-MIBG and <sup>18</sup>F-MFBG findings were evaluated for concordance and discordance. Modified Curie scores were assigned to both <sup>123</sup>I-MIBG scans, equivalent scores were ascertained for <sup>18</sup>F-MFBG imaging, and scores were then compared. <strong>Results:</strong> All patients with a positive <sup>123</sup>I-MIBG scan had positive <sup>18</sup>F-MFBG imaging. In 2 patients, both <sup>123</sup>I-MIBG and <sup>18</sup>F-MFBG scans were negative. In 1 patient, the <sup>18</sup>F-MFBG scan was positive, whereas the <sup>123</sup>I-MIBG scan was negative. In 30 of 40 scans, <sup>18</sup>F-MFBG showed more sites than did <sup>123</sup>I-MIBG. Overall, more lesions were noted on the <sup>18</sup>F-MFBG scans (mean, 18; range 0–61) compared with the <sup>123</sup>I-MIBG scans (mean, 12; range, 0–44), and 455 lesions were concordant. The Curie score for <sup>18</sup>F-MFBG was higher, with an average of 11 (range, 0–25) compared with 8 for <sup>123</sup>I-MIBG (range, 0–22). Of the 273 <sup>18</sup>F-MFBG–positive/<sup>123</sup>I-MIBG–negative lesions, follow-up clinical and imaging assessment was available for 234 lesions in 30 patients, and 100% of these were confirmed true-positive. <strong>Conclusion:</strong> <sup>18</sup>F-MFBG PET offers faster imaging and superior detection compared with <sup>123</sup>I-MIBG imaging. <sup>18</sup>F-MFBG had high concordance with <sup>123</sup>I-MIBG at the patient level and showed more lesions in most patients. <sup>18</sup>F-MFBG is an attractive alternative to <sup>123</sup>I-MIBG.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"39 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lesion Analysis of 18F-Metafluorobenzylguanidine PET Imaging in Neuroblastoma\",\"authors\":\"Neeta Pandit-Taskar, Ellen Basu, Ali Pirasteh, Gerald Behr, Audrey Mauguen, Jazmin Schwartz, Serge Lyashchenko, Scott Vietri, Eva Burnazi, Anita P. Price, Shakeel Modak\",\"doi\":\"10.2967/jnumed.125.269833\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>A PET analog of metaiodobenzylguanidine (MIBG)—<sup>18</sup>F-metafluorobenzylguanidine (<sup>18</sup>F-MFBG)—allows for rapid same-day imaging. We previously reported on the safety and feasibility of <sup>18</sup>F-MFBG PET imaging in patients with neuroendocrine tumors. We now report a comprehensive analysis of lesion detection with <sup>18</sup>F-MFBG imaging in patients with neuroblastoma compared with <sup>123</sup>I-MIBG imaging. <strong>Methods:</strong> We analyzed concurrent <sup>18</sup>F-MFBG and <sup>123</sup>I-MIBG scans in 37 patients (40 paired scans). Patients with relapsed or refractory neuroblastoma were included. Patients received 74.11–465.83 MBq (2.0–12.6 mCi) of <sup>18</sup>F-MFBG intravenously, followed by imaging 60 min after injection. All patients had an <sup>123</sup>I-MIBG scan within 4 wk of <sup>18</sup>F-MFBG imaging without any intervening therapy. <sup>123</sup>I-MIBG scans included whole-body planar and SPECT/CT of the chest, abdomen, and pelvis. All detected lesions were noted for each modality. <sup>123</sup>I-MIBG and <sup>18</sup>F-MFBG findings were evaluated for concordance and discordance. Modified Curie scores were assigned to both <sup>123</sup>I-MIBG scans, equivalent scores were ascertained for <sup>18</sup>F-MFBG imaging, and scores were then compared. <strong>Results:</strong> All patients with a positive <sup>123</sup>I-MIBG scan had positive <sup>18</sup>F-MFBG imaging. In 2 patients, both <sup>123</sup>I-MIBG and <sup>18</sup>F-MFBG scans were negative. In 1 patient, the <sup>18</sup>F-MFBG scan was positive, whereas the <sup>123</sup>I-MIBG scan was negative. In 30 of 40 scans, <sup>18</sup>F-MFBG showed more sites than did <sup>123</sup>I-MIBG. Overall, more lesions were noted on the <sup>18</sup>F-MFBG scans (mean, 18; range 0–61) compared with the <sup>123</sup>I-MIBG scans (mean, 12; range, 0–44), and 455 lesions were concordant. The Curie score for <sup>18</sup>F-MFBG was higher, with an average of 11 (range, 0–25) compared with 8 for <sup>123</sup>I-MIBG (range, 0–22). Of the 273 <sup>18</sup>F-MFBG–positive/<sup>123</sup>I-MIBG–negative lesions, follow-up clinical and imaging assessment was available for 234 lesions in 30 patients, and 100% of these were confirmed true-positive. <strong>Conclusion:</strong> <sup>18</sup>F-MFBG PET offers faster imaging and superior detection compared with <sup>123</sup>I-MIBG imaging. <sup>18</sup>F-MFBG had high concordance with <sup>123</sup>I-MIBG at the patient level and showed more lesions in most patients. <sup>18</sup>F-MFBG is an attractive alternative to <sup>123</sup>I-MIBG.</p>\",\"PeriodicalId\":22820,\"journal\":{\"name\":\"The Journal of Nuclear Medicine\",\"volume\":\"39 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Nuclear Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2967/jnumed.125.269833\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2967/jnumed.125.269833","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Lesion Analysis of 18F-Metafluorobenzylguanidine PET Imaging in Neuroblastoma
A PET analog of metaiodobenzylguanidine (MIBG)—18F-metafluorobenzylguanidine (18F-MFBG)—allows for rapid same-day imaging. We previously reported on the safety and feasibility of 18F-MFBG PET imaging in patients with neuroendocrine tumors. We now report a comprehensive analysis of lesion detection with 18F-MFBG imaging in patients with neuroblastoma compared with 123I-MIBG imaging. Methods: We analyzed concurrent 18F-MFBG and 123I-MIBG scans in 37 patients (40 paired scans). Patients with relapsed or refractory neuroblastoma were included. Patients received 74.11–465.83 MBq (2.0–12.6 mCi) of 18F-MFBG intravenously, followed by imaging 60 min after injection. All patients had an 123I-MIBG scan within 4 wk of 18F-MFBG imaging without any intervening therapy. 123I-MIBG scans included whole-body planar and SPECT/CT of the chest, abdomen, and pelvis. All detected lesions were noted for each modality. 123I-MIBG and 18F-MFBG findings were evaluated for concordance and discordance. Modified Curie scores were assigned to both 123I-MIBG scans, equivalent scores were ascertained for 18F-MFBG imaging, and scores were then compared. Results: All patients with a positive 123I-MIBG scan had positive 18F-MFBG imaging. In 2 patients, both 123I-MIBG and 18F-MFBG scans were negative. In 1 patient, the 18F-MFBG scan was positive, whereas the 123I-MIBG scan was negative. In 30 of 40 scans, 18F-MFBG showed more sites than did 123I-MIBG. Overall, more lesions were noted on the 18F-MFBG scans (mean, 18; range 0–61) compared with the 123I-MIBG scans (mean, 12; range, 0–44), and 455 lesions were concordant. The Curie score for 18F-MFBG was higher, with an average of 11 (range, 0–25) compared with 8 for 123I-MIBG (range, 0–22). Of the 273 18F-MFBG–positive/123I-MIBG–negative lesions, follow-up clinical and imaging assessment was available for 234 lesions in 30 patients, and 100% of these were confirmed true-positive. Conclusion:18F-MFBG PET offers faster imaging and superior detection compared with 123I-MIBG imaging. 18F-MFBG had high concordance with 123I-MIBG at the patient level and showed more lesions in most patients. 18F-MFBG is an attractive alternative to 123I-MIBG.